MA45223A - Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant - Google Patents
Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenantInfo
- Publication number
- MA45223A MA45223A MA045223A MA45223A MA45223A MA 45223 A MA45223 A MA 45223A MA 045223 A MA045223 A MA 045223A MA 45223 A MA45223 A MA 45223A MA 45223 A MA45223 A MA 45223A
- Authority
- MA
- Morocco
- Prior art keywords
- subsitated
- hetero
- aryl
- pharmaceutical compositions
- preparation process
- Prior art date
Links
- -1 PIPERIDINYL Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L’invention concerne des composés de formule (i), dans laquelle r<sub>1</sub>, r<sub>2</sub>, j, k, l, n et w sont tels que définis dans la description. L'invention concerne également des médicaments.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1655387A FR3052451B1 (fr) | 2016-06-10 | 2016-06-10 | Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR1663463A FR3061177B1 (fr) | 2016-12-28 | 2016-12-28 | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| PCT/EP2017/064062 WO2017212010A1 (fr) | 2016-06-10 | 2017-06-09 | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45223A true MA45223A (fr) | 2019-04-17 |
| MA45223B1 MA45223B1 (fr) | 2020-04-30 |
Family
ID=59021522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45223A MA45223B1 (fr) | 2016-06-10 | 2017-06-09 | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant |
Country Status (42)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018067964B1 (pt) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc | Composto, composição farmacêutica que o compreende e uso do referido composto |
| FR3052452B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN118021814A (zh) | 2017-04-21 | 2024-05-14 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| IL272941B2 (en) | 2017-08-28 | 2023-03-01 | Enanta Pharm Inc | Antiviral agents for viral hepatitis b |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
| UY38291A (es) * | 2018-07-05 | 2020-06-30 | Servier Lab | Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas |
| WO2020061435A1 (fr) | 2018-09-21 | 2020-03-26 | Enanta Pharmaceuticals, Inc. | Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux |
| UY38423A (es) * | 2018-10-19 | 2021-02-26 | Servier Lab | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen |
| KR102819704B1 (ko) | 2018-11-21 | 2025-06-11 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스제로서의 작용화된 헤테로사이클 |
| WO2020115501A1 (fr) * | 2018-12-06 | 2020-06-11 | Almac Discovery Limited | Composés pharmaceutiques et leur utilisation en tant qu'inhibiteurs de la protéase 19 spécifique de l'ubiquitine (usp19) |
| WO2020227365A1 (fr) * | 2019-05-06 | 2020-11-12 | Integral Early Discovery, Inc. | Inhibition de l'usp19 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| PL3994130T3 (pl) | 2019-07-03 | 2024-11-18 | Bayer Aktiengesellschaft | Podstawione tiofenokarboksyamidy i ich pochodne jako mikrobiocydy |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (fr) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux |
| CN118496197A (zh) | 2019-12-20 | 2024-08-16 | 拜耳公司 | 取代的噻吩甲酰胺、噻吩甲酸及其衍生物 |
| CN113087718B (zh) * | 2020-01-09 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 噻吩并嘧啶酮类化合物及其医药应用 |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| WO2021188414A1 (fr) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Composés hétérocycliques fonctionnalisés utiles en tant qu'agents antiviraux |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| CN116574084A (zh) * | 2023-04-17 | 2023-08-11 | 华南理工大学 | 一种噻吩衍生物及其合成方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200840571A (en) * | 2007-03-02 | 2008-10-16 | Schering Corp | Piperidine derivatives and methods of use thereof |
| EP2565186A1 (fr) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| JP2018504431A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン |
| JP2018504430A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン |
| EP3253759A1 (fr) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, et pyrrolopyrimidinones, en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7 |
-
2017
- 2017-06-09 GE GEAP201714982A patent/GEP20207161B/en unknown
- 2017-06-09 LT LTEP17728567.3T patent/LT3468971T/lt unknown
- 2017-06-09 MY MYPI2018002417A patent/MY196328A/en unknown
- 2017-06-09 CN CN201780047088.4A patent/CN109563094B/zh active Active
- 2017-06-09 EP EP17728567.3A patent/EP3468971B1/fr active Active
- 2017-06-09 JP JP2018564752A patent/JP6985299B2/ja not_active Expired - Fee Related
- 2017-06-09 CR CR20180563A patent/CR20180563A/es unknown
- 2017-06-09 AU AU2017277732A patent/AU2017277732B2/en not_active Ceased
- 2017-06-09 KR KR1020197000798A patent/KR102003532B1/ko active Active
- 2017-06-09 WO PCT/EP2017/064062 patent/WO2017212010A1/fr not_active Ceased
- 2017-06-09 PL PL17728567T patent/PL3468971T3/pl unknown
- 2017-06-09 SG SG11201810576QA patent/SG11201810576QA/en unknown
- 2017-06-09 BR BR112018075284-3A patent/BR112018075284A2/pt not_active Application Discontinuation
- 2017-06-09 DK DK17728567.3T patent/DK3468971T3/da active
- 2017-06-09 MA MA45223A patent/MA45223B1/fr unknown
- 2017-06-09 HR HRP20200556TT patent/HRP20200556T1/hr unknown
- 2017-06-09 UY UY0001037289A patent/UY37289A/es unknown
- 2017-06-09 SI SI201730267T patent/SI3468971T1/sl unknown
- 2017-06-09 MX MX2018015212A patent/MX374443B/es active IP Right Grant
- 2017-06-09 HU HUE17728567A patent/HUE048590T2/hu unknown
- 2017-06-09 PT PT177285673T patent/PT3468971T/pt unknown
- 2017-06-09 CU CU2018000146A patent/CU20180146A7/es unknown
- 2017-06-09 US US16/306,941 patent/US10654849B2/en active Active
- 2017-06-09 MD MDE20190461T patent/MD3468971T2/ro unknown
- 2017-06-09 GE GEAP202014982A patent/GEAP202014982A/en unknown
- 2017-06-09 PE PE2018003132A patent/PE20220948A1/es unknown
- 2017-06-09 CA CA3027008A patent/CA3027008C/fr active Active
- 2017-06-09 ES ES17728567T patent/ES2778700T3/es active Active
- 2017-06-09 RU RU2018147424A patent/RU2742271C2/ru active
- 2017-06-09 UA UAA201900070A patent/UA123793C2/uk unknown
- 2017-06-09 TN TNP/2018/000395A patent/TN2018000395A1/en unknown
- 2017-06-09 RS RS20200510A patent/RS60279B1/sr unknown
- 2017-06-09 TW TW106119243A patent/TWI647228B/zh not_active IP Right Cessation
-
2018
- 2018-11-28 PH PH12018502516A patent/PH12018502516B1/en unknown
- 2018-11-29 SV SV2018005792A patent/SV2018005792A/es unknown
- 2018-12-03 IL IL263455A patent/IL263455B/en active IP Right Grant
- 2018-12-03 DO DO2018000264A patent/DOP2018000264A/es unknown
- 2018-12-04 CO CONC2018/0013141A patent/CO2018013141A2/es unknown
- 2018-12-04 EC ECSENADI201890046A patent/ECSP18090046A/es unknown
- 2018-12-04 CL CL2018003473A patent/CL2018003473A1/es unknown
- 2018-12-07 ZA ZA2018/08286A patent/ZA201808286B/en unknown
- 2018-12-07 NI NI201800133A patent/NI201800133A/es unknown
-
2020
- 2020-05-18 CY CY20201100451T patent/CY1123069T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45223A (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA45222B1 (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA42231B1 (fr) | Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA42230B1 (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA42232B1 (fr) | Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| TN2016000014A1 (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| MA35750B1 (fr) | Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c) | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| FR2986002A1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MA55046B1 (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| MA38287B1 (fr) | Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA38854A1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| FR3041639B1 (fr) | NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA41174B1 (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta |